Flory James H, Ky Bonnie, Haynes Kevin, M Brunelli Steve, Munson Jeffrey, Rowan Christopher, Strom Brian L, Hennessy Sean
Division of Endocrinology, Diabetes, and Metabolism in the Department of Medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
BMJ Open. 2012 Apr 13;2(2):e000888. doi: 10.1136/bmjopen-2012-000888. Print 2012.
This study aims to assess whether digoxin has a different effect on mortality risk for women than it does for men in patients with heart failure (HF).
This study uses the UK-based The Health Information Network population database in a cohort study of the impact of digoxin exposure on mortality for men and women who carry the diagnosis of HF. Digoxin exposure was assessed based on prescribing data. Multivariable Cox proportional hazards models were used to assess whether there was an interaction between sex and digoxin affecting mortality hazard.
The setting was primary care outpatient practices.
The study cohort consisted of 17 707 men and 19 227 women with the diagnosis of HF who contributed only time without digoxin exposure and 9487 men and 10 808 women with the diagnosis of HF who contributed time with digoxin exposure.
The main outcome measure was all-cause mortality.
The primary outcome of this study was the absence of a large interaction between digoxin use and sex affecting mortality. For men, digoxin use was associated with a HR for mortality of 1.00, while for women, the HR was also 1.00 (p value for interaction 0.65). The results of sensitivity analyses were consistent with those of the primary analysis.
Observational data do not support the concern that there is a substantial increased risk of mortality due to the use of digoxin in women. This finding is consistent with previous observational studies but discordant with results from a post hoc analysis of a randomised controlled trial of digoxin versus placebo.
本研究旨在评估在心力衰竭(HF)患者中,地高辛对女性死亡风险的影响是否与男性不同。
本研究使用英国的健康信息网络人口数据库,对诊断为HF的男性和女性进行队列研究,以评估地高辛暴露对死亡率的影响。根据处方数据评估地高辛暴露情况。使用多变量Cox比例风险模型评估性别与地高辛之间是否存在影响死亡风险的相互作用。
研究地点为基层医疗门诊。
研究队列包括17707名诊断为HF且仅贡献无地高辛暴露时间的男性和19227名女性,以及9487名诊断为HF且贡献有地高辛暴露时间的男性和10808名女性。
主要结局指标为全因死亡率。
本研究的主要结果是地高辛使用与性别之间不存在影响死亡率的显著相互作用。对于男性,使用地高辛与死亡率的风险比(HR)为1.00,而对于女性,HR也为1.00(相互作用的p值为0.65)。敏感性分析结果与主要分析结果一致。
观察性数据不支持因女性使用地高辛而导致死亡风险大幅增加的担忧。这一发现与先前的观察性研究一致,但与地高辛与安慰剂随机对照试验的事后分析结果不一致。